Scott Bruder, Md, Phd Email and Phone Number
Scott Bruder, Md, Phd work email
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
- Valid
Scott Bruder, Md, Phd personal email
- Valid
Scott Bruder, Md, Phd phone numbers
Insightful and energetic healthcare leader with a 30-plus year history of bridging basic science, clinical medicine, and industrial development expertise to deliver innovative, commercially successful products that improve patients’ lives around the world. Experience in medical devices, biotechnology, cell therapy, diagnostics and life science research tools fortify an expansive analytical skill set for this resilient, poised and influential C-Suite executive. An award-winning scientist and clinician, equally comfortable in the laboratory, at the lectern, in the Boardroom or on Capitol Hill, he delivers impactful results by inspiring multi-disciplinary teams to be collaborative, rigorous and decisive. This seasoned Senior Executive, University Professor, Board Member and former FDA Advisory Committee Member provides a unique bench-to-bedside perspective on unmet needs, development strategy and the path to commercialization. An avid long-distance runner, jazz pianist, devoted husband and dedicated father, his core beliefs are based on the principles of passion, commitment and discipline. Read more about the Bruder Consulting & Venture Group at www.bruderconsulting.com
-
Founder And CeoBruder Consulting & Venture Group Nov 2014 - PresentMetro Nyc, UsThe Bruder Consulting & Venture Group (www.bruderconsulting.com) provides services to start-up through multi-national conglomerate medical device, regenerative medicine and biotechnology companies, investment banks, venture partners and private equity firms. The company’s dedicated team of executive Engagement Partners offers clients a diversified expertise in technology, product and market development, clinical and regulatory affairs, reimbursement and health economics, and commercialization strategy, including financial and/or strategic partnering. Agreements with exceptional “Affiliate Firms” that provide complimentary services to the Group, such as laboratory and animal studies for regulatory approval, global clinical trial execution, and intellectual property analysis and valuation, along with a set of world renown "Special Advisors" from academia, distinguish the Group from more traditional boutique consulting firms. Clients include companies in the United States, Canada, Europe, Israel, China, and Japan.
-
Professor Of Biomedical Engineering (Adjunct)Case Western Reserve University 1998 - PresentCleveland, Oh, UsWith strong initiatives in education and translational research, as well as aggressive faculty recruitment, the Department of Biomedical Engineering at Case Western Reserve University is positioning itself as a leader for many years to come. (Served 13 years as Adjunct Faculty in the Department of Orthopaedic Surgery before appointment to Biomedical Engineering). -
Senior Advisor, Orthopaedics And Regenerative MedicineWombat Capital Mar 2015 - PresentNew York, UsWombat Capital is a cross-border investment banking, financial and strategic advisory firm. Services include M&A, Debt & Equity Financing, Valuation and Fairness Opinions, Joint Ventures and Strategic Alliances. Our focus is in three major industries: Life Sciences (Pharma, Biotech, Contract Services, Diagnostics, Medical Devices, Healthcare), Life Style (Fashion, Retail, Luxury Goods, Consumer Products), and TMT (Technology, Media & Telecommunications). Wombat has offices in New York and Paris. -
Board Of Directors MemberKuros Biosurgery Ag Jun 2018 - Apr 2024Schlieren, Zurich, ChKuros Biosciences (SIX Swiss Exchange: KURN) has spent more than a decade refining technologies that instruct the body to form bone using targeted and controlled mechanisms of action. In early 2017 Kuros acquired Xpand Biotechnology, adding substantial expertise in the surface science of orthobiologics & delivering the next generation MagnetOs family of bone grafts to our portfolio. In 2018, the firm achieved FDA clearances to commercialize in the USA while also working to develop combination products for bone regeneration. -
Board Of Directors MemberBellerophon Therapeutics May 2015 - Feb 2024Warren, New Jersey, UsBellerophon Therapeutics (Nasdaq: BLPH) is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need. -
Chairman Of The BoardSpinal Elements, Inc. Apr 2016 - May 2018Carlsbad, California, UsSpinal Elements is a leading provider of innovative medical devices and biologic implants used during spinal surgical procedures. In 2017, Amendia, Inc., acquired the Carlsbad, CA firm, and rebranded the combined entity as Spinal Elements. The company's mission is to exceed surgeon and patient expectations by creating balanced solutions with disruptive technologies for medical devices paired with biologics and instrumentation. The firm's bi-coastal presence and vertically-integrated strategy focuses on improving surgical outcomes and the lives of patients with spinal disorders. -
Chief Medical And Scientific OfficerStryker Corporation Dec 2012 - Nov 2014Kalamazoo, Mi, UsSenior executive responsible for overseeing the clinical and scientific efforts across the $9 billion Corporation, including academic, industrial and governmental scientific partnerships. Served as the Company's first-ever CMSO, and represented Stryker as the senior medical and scientific authority at trade associations, scientific meetings, regulatory agencies and various other entities as necessary. Successfully developed and deployed company-wide programs to drive innovation, clinical & health economic evidence generation, and monetization of stranded intellectual property and technology assets. -
Chief Science And Technology OfficerBecton, Dickinson And Company Sep 2007 - Oct 2012Franklin Lakes, New Jersey, UsSenior executive responsible for providing technology, strategy and product development leadership across the entire $8 billion Medical Device, Diagnostics and Bioscience business. Accountable for identifying and cultivating new growth and innovation opportunities, leading the Corporate Research Center, developing a pipeline of science and technology leaders, and integrating a Worldwide Research & Development portfolio, including allocation of a ~$500 million operating budget with almost 2,000 R&D associates. -
Worldwide Vice President, Johnson & Johnson Regenerative TherapeuticsJohnson & Johnson 2005 - 2007New Brunswick, Nj, UsLed the development of a corporate-wide strategic plan, and successfully capitalized, created and managed a new business unit known as Johnson & Johnson Regenerative Therapeutics, LLC. Designed and executed business plans for product development across multiple J&J operating companies, including DePuy (Musculoskeletal), Ethicon (General Surgery, and Women’s Health & Urology), Codman (Neurobiology) and Cordis (Cardiovascular). -
Worldwide Vice President, Depuy BiologicsDepuy Synthes Companies 2000 - 2005Raynham, Ma, UsSystematically created the musculoskeletal tissue regeneration (Orthobiologic) capabilities from conception to a multi-disciplinary division across DePuy Orthopaedics, Spine, Mitek and Codman, eventually evolving into a separate organization known as DePuy Biologics (ultimately acquired by J&J Regenerative Therapeutics, LLC). -
Vice President, Research & DevelopmentAnika Therapeutics 1998 - 2000Bedford, Ma, UsConceived and directed the overall strategic plan for the Company's Research, Development and Clinical programs in "Tissue Repair, Protection and Healing", based on a hyaluronic acid biomaterial platform technology. Evaluated and organized relationships with academic and industrial partners, including new technology assessment and IP. -
Director, Bone And Soft Tissue RegenerationOsiris Therapeutics 1994 - 1998UsEnsured comprehensive technology transfer from the founding academic laboratories at CWRU, to the Company (as its third employee). Translated the hypothetical tissue reparative applications of mesenchymal stem cells into reproducible therapies that effectively scaled up from rodents to large animals and ultimately humans.
Scott Bruder, Md, Phd Skills
Scott Bruder, Md, Phd Education Details
-
Brown UniversityGeneral -
Case Western Reserve UniversityCell/Cellular And Molecular Biology
-
Case Western Reserve UniversityMedicine
Frequently Asked Questions about Scott Bruder, Md, Phd
What company does Scott Bruder, Md, Phd work for?
Scott Bruder, Md, Phd works for Bruder Consulting & Venture Group
What is Scott Bruder, Md, Phd's role at the current company?
Scott Bruder, Md, Phd's current role is Founder and CEO, Physician-Scientist Executive, Board Member.
What is Scott Bruder, Md, Phd's email address?
Scott Bruder, Md, Phd's email address is scottbruder@me.com
What is Scott Bruder, Md, Phd's direct phone number?
Scott Bruder, Md, Phd's direct phone number is +120183*****
What schools did Scott Bruder, Md, Phd attend?
Scott Bruder, Md, Phd attended Brown University, Case Western Reserve University, Case Western Reserve University.
What skills is Scott Bruder, Md, Phd known for?
Scott Bruder, Md, Phd has skills like Biotechnology, Medical Devices, Biomedical Engineering, Fda, Commercialization, Lifesciences, Life Sciences, R&d, Technology Transfer, Product Development, Strategy, Clinical Research.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial